Pathologies in Cdk4 R24C; Cdk6 R31C compound mice
| Pathology . | Cdk4+/+;Cdk6+/+ . | Cdk4R/R; Cdk6+/+ . | Cdk4+/+;Cdk6R/R . | Cdk4R/R; Cdk6R/R . |
|---|---|---|---|---|
| n = 20 . | n = 12 . | n = 16 . | n = 18 . | |
| Tumoral or pretumoral phenotypes | ||||
| Acinar cell adenoma (pancreas) | 5% (103) | 0% | 0% | 0% |
| Angiosarcoma | 0% | 58% (68) | 38% (89) | 11% (72) |
| Bronchial adenocarcinoma | 5% (118) | 33% (71) | 38% (114) | 0% |
| Fibrosarcoma | 5% (80) | 8% (64) | 0% | 0% |
| Histiocytic sarcoma | 5% (86) | 0% | 0% | 22% (54) |
| Leydig cell hyperplasia | 0% | 17% (71) | 0% | 50% (52) |
| Leydig cell tumor | 0% | 50% (69) | 0% | 50% (61) |
| Lung tumors | 0% | 0% | 0% | 11% (61) |
| Lymphoma | 10% (88) | 0% | 19% (83) | 39% (62) |
| Mammary gland hyperplasia | 10% (92) | 17% (83) | 19% (83) | 39% (59) |
| Pancreatic endocrine hyperplasia | 20% (112) | 33% (65) | 19% (84) | 50% (54) |
| Pancreatic endocrine tumor | 0% | 25% (70) | 13% (97) | 11% (72) |
| Pituitary gland hyperplasia | 0% | 17% (54) | 13% (90) | 22% (49) |
| Pituitary gland tumors | 10% (92) | 25% (76) | 13% (77) | 72% (61) |
| T-cell hyperplasia | 5% (80) | 17% (65) | 50% (114) | 0% |
| Rhabdomyosarcoma | 0% | 0% | 13% (139) | 0% |
| Total incidence | 50% | 94% | 88% | 83% |
| Average latency | 97.3 | 69 | 99 | 58.3 |
| Nontumoral phenotypes | ||||
| Bronchus-associated lymphoid tissue | 0% | 0% | 31% (101) | 0% |
| Cardiac defects | 20% (102) | 0% | 13% (85) | 39% (55) |
| Chronic hepatitis | 5% (107) | 0% | 13% (70) | 0% |
| Chronic pancreatitis | 30% (78) | 0% | 13% (85) | 10% (36) |
| Extramedullary hematopoiesis | 5% (103) | 58% (71) | 19% (114) | 22% (50) |
| Kidney disease | 20% (96) | 17% (66) | 19% (104) | 89% (57) |
| Liver steatosis | 20% (91) | 0% | 0% | 11% (44) |
| Megakaryocyte malformation | 0% | 0% | 0% | 78% (60) |
| Splenic atrophy | 0% | 0% | 13% (97) | 0% |
| Vasculitis | 5% (81) | 0% | 19% (90) | 0% |
| Pathology . | Cdk4+/+;Cdk6+/+ . | Cdk4R/R; Cdk6+/+ . | Cdk4+/+;Cdk6R/R . | Cdk4R/R; Cdk6R/R . |
|---|---|---|---|---|
| n = 20 . | n = 12 . | n = 16 . | n = 18 . | |
| Tumoral or pretumoral phenotypes | ||||
| Acinar cell adenoma (pancreas) | 5% (103) | 0% | 0% | 0% |
| Angiosarcoma | 0% | 58% (68) | 38% (89) | 11% (72) |
| Bronchial adenocarcinoma | 5% (118) | 33% (71) | 38% (114) | 0% |
| Fibrosarcoma | 5% (80) | 8% (64) | 0% | 0% |
| Histiocytic sarcoma | 5% (86) | 0% | 0% | 22% (54) |
| Leydig cell hyperplasia | 0% | 17% (71) | 0% | 50% (52) |
| Leydig cell tumor | 0% | 50% (69) | 0% | 50% (61) |
| Lung tumors | 0% | 0% | 0% | 11% (61) |
| Lymphoma | 10% (88) | 0% | 19% (83) | 39% (62) |
| Mammary gland hyperplasia | 10% (92) | 17% (83) | 19% (83) | 39% (59) |
| Pancreatic endocrine hyperplasia | 20% (112) | 33% (65) | 19% (84) | 50% (54) |
| Pancreatic endocrine tumor | 0% | 25% (70) | 13% (97) | 11% (72) |
| Pituitary gland hyperplasia | 0% | 17% (54) | 13% (90) | 22% (49) |
| Pituitary gland tumors | 10% (92) | 25% (76) | 13% (77) | 72% (61) |
| T-cell hyperplasia | 5% (80) | 17% (65) | 50% (114) | 0% |
| Rhabdomyosarcoma | 0% | 0% | 13% (139) | 0% |
| Total incidence | 50% | 94% | 88% | 83% |
| Average latency | 97.3 | 69 | 99 | 58.3 |
| Nontumoral phenotypes | ||||
| Bronchus-associated lymphoid tissue | 0% | 0% | 31% (101) | 0% |
| Cardiac defects | 20% (102) | 0% | 13% (85) | 39% (55) |
| Chronic hepatitis | 5% (107) | 0% | 13% (70) | 0% |
| Chronic pancreatitis | 30% (78) | 0% | 13% (85) | 10% (36) |
| Extramedullary hematopoiesis | 5% (103) | 58% (71) | 19% (114) | 22% (50) |
| Kidney disease | 20% (96) | 17% (66) | 19% (104) | 89% (57) |
| Liver steatosis | 20% (91) | 0% | 0% | 11% (44) |
| Megakaryocyte malformation | 0% | 0% | 0% | 78% (60) |
| Splenic atrophy | 0% | 0% | 13% (97) | 0% |
| Vasculitis | 5% (81) | 0% | 19% (90) | 0% |
Bold-faced type indicates major differences compared with control groups.